Prognostic impacts of tumoral expression and serum levels of PD-L1 and CTLA-4 in colorectal cancer patients

被引：0
|
作者：
Yusuke Omura
Yuji Toiyama
Yoshinaga Okugawa
Chengzeng Yin
Tsunehiko Shigemori
Kurando Kusunoki
Yukina Kusunoki
Shozo Ide
Tadanobu Shimura
Hiroyuki Fujikawa
Hiromi Yasuda
Junichiro Hiro
Masaki Ohi
Masato Kusunoki
机构：
[1] Mie University Graduate School of Medicine,Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences
[2] Mie University Hospital,Department of Genomic Medicine
来源：
Cancer Immunology, Immunotherapy | 2020年 / 69卷
关键词：
Tumoral membrane expression; Soluble receptors and ligands; PD-L1; CTLA-4; Colorectal Cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2533 / 2546
页数：13
相关论文
共 50 条
  • [21] Association of PD-1, PD-L1, and CTLA-4 Gene Expression and Clinicopathologic Characteristics in Patients With Non-Small-Cell Lung Cancer
    Lafuente-Sanchis, Aranzazu
    Zuniga, Angel
    Estors, Miriam
    Martinez-Hernandez, Nestor J.
    Cremades, Antonio
    Cuenca, Maria
    Galbis, Jose M.
    CLINICAL LUNG CANCER, 2017, 18 (02) : E109 - E116
  • [22] Immune Checkpoint (PD-1, PD-L1, PD-L2, and CTLA-4) Expression in Plasma Cell Myeloma
    Lee, Min Young
    Park, Chan-jeoung
    Cho, Young-Uk
    You, Eunkyoung
    Jang, Seongsoo
    Lee, Jung-Hee
    Hong, Jung Yong
    Yoon, Dok Hyun
    Suh, Cheolwon
    BLOOD, 2017, 130
  • [23] Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
    Feng, Yuqian
    Jin, Huimin
    Guo, Kaibo
    Xiang, Yuying
    Zhang, Yiting
    Du, Wurong
    Shen, Minhe
    Ruan, Shanming
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [24] Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
    S A Quezada
    K S Peggs
    British Journal of Cancer, 2013, 108 : 1560 - 1565
  • [25] Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer
    Quezada, S. A.
    Peggs, K. S.
    BRITISH JOURNAL OF CANCER, 2013, 108 (08) : 1560 - 1565
  • [26] Prognostic significance of PD-L1 expression in patients with colorectal cancer: a meta-analysis
    Siwen Liu
    Rong Ma
    Haixia Cao
    Dan Chen
    Changwen Jing
    Zhuo Wang
    Junying Zhang
    Yang Wu
    Jifeng Feng
    Jianzhong Wu
    OncologyandTranslationalMedicine, 2019, 5 (02) : 68 - 74
  • [27] The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix
    Mobarki, M.
    Karpathiou, G.
    Da Cruz, V.
    Chauleur, C.
    Forest, F.
    Peoc'h, M.
    VIRCHOWS ARCHIV, 2017, 471 : S80 - S80
  • [28] The immune checkpoints CTLA-4 and PD-L1 in carcinomas of the uterine cervix
    Karpathiou, Georgia
    Chauleur, Celine
    Mobarki, Mousa
    Peoc'h, Michel
    PATHOLOGY RESEARCH AND PRACTICE, 2020, 216 (01)
  • [29] Cancer combination therapies by silencing of CTLA-4, PD-L1, and TIM3 in osteosarcoma
    Sorkhabi, Amin Daei
    Sarkesh, Aila
    Fotouhi, Ali
    Saeedi, Hossein
    Aghebati-Maleki, Leili
    IUBMB LIFE, 2022, 74 (09) : 908 - 917
  • [30] Immune checkpoint therapy: From CTLA-4 to PD-1/PD-L1 and beyond
    Sharma, Padmanee
    CANCER RESEARCH, 2018, 78 (13)
12345